Organogenesis Holdings Croissance future
Future contrôle des critères 0/6
Le chiffre d'affaires de Organogenesis Holdings devrait diminuer de 10.8% par an, tandis que ses bénéfices annuels devraient croître de 51.5% par an. Le BPA devrait croître de , augmenter de 51.9% par an.
Informations clés
51.5%
Taux de croissance des bénéfices
51.88%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 29.1% |
| Taux de croissance des recettes | -10.8% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 07 Aug 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Aug 09
ORGO: Reimbursement Pressures And Knee OA BLA Will Shape Balanced Future Prospects
Analysts have lowered their price target on Organogenesis Holdings stock from $3 to $2, citing updated expectations that take into account ongoing reimbursement-driven pressures on revenue and margins, as well as a lower assumed future P/E multiple. Analyst Commentary Recent research on Organogenesis Holdings highlights a mix of potential opportunity and clear near term challenges.Mise à jour du récit • Jun 23
ORGO: Reimbursement Reset And Knee OA BLA Will Support Future Upside
Analysts have kept their $3 price target on Organogenesis Holdings intact, citing the view that reimbursement changes and a potential shakeout among smaller competitors could eventually help the company, while recently lowered guidance and limited near term revenue upside restrain expectations. What's in the News Organogenesis Holdings issued earnings guidance for the first half, second half, and full year 2026, indicating total net revenue in a range of $270.0 million to $310.0 million compared with $564.2 million reported for full year 2025, based on company guidance.Seeking Alpha • Jun 15
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked
Summary Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026 guidance now calls for a 45–52% year-over-year revenue drop to $270–310 million. Market headwinds have intensified, with clinicians in some cases moving away from skin substitutes entirely, compounding ORGO's challenges. Management anticipates a gradual turnaround through 2026, with a potential acceleration in Q4. ReNu, its knee injection with a novel MOA and blockbuster potential, is awaiting FDA approval of its pending BLA. Read the full article on Seeking AlphaMise à jour du récit • Jun 01
ORGO: Reimbursement Shakeout And Knee Osteoarthritis BLA Will Drive Future Upside
Analysts reduced their price target on Organogenesis Holdings to $3, citing reimbursement-driven structural shifts that could eventually benefit the company as smaller competitors exit. They also pointed to limited near-term revenue upside after management lowered guidance to reflect a steeper expected decline in 2026.
Mise à jour du récit • Feb 19
ORGO: FDA Rolling BLA For Knee Osteoarthritis Will Support Bullish Outlook
Analysts have maintained their $8.00 price target on Organogenesis Holdings, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Organogenesis completed a planned Type B meeting with the FDA, securing confirmation to begin a rolling Biologics License Application for ReNu, with the filing expected to start before the end of December (Key Developments).Mise à jour du récit • Feb 05
ORGO: FDA BLA Progress For Knee Osteoarthritis Will Support Bullish Outlook
Analysts have slightly trimmed their price targets on Organogenesis Holdings, citing updated assumptions that include a modestly higher discount rate, slightly stronger revenue growth and profit margin estimates, and a somewhat lower future P/E multiple. What's in the News Organogenesis Holdings reported a successful Type B meeting with the FDA that cleared the way to start a rolling Biologics License Application, or BLA, for its ReNu product, with filing planned before the end of December (Key Developments).Mise à jour du récit • Jan 21
ORGO: FDA Rolling Submission For Knee Osteoarthritis Therapy Will Support Bullish Outlook
Analysts have nudged their price target on Organogenesis Holdings higher to US$8.00, citing slightly firmer assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Completed a planned Type B meeting with the FDA, receiving confirmation to initiate a rolling Biologics License Application for ReNu, targeted before the end of December (Key Developments).Article d’analyse • Jan 17
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28%
Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shareholders won't be pleased to see that the share price has had a very...Article d’analyse • Jan 11
Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Mise à jour du récit • Jan 06
ORGO: Regulatory Momentum For Knee Osteoarthritis Therapy Will Support Bullish Outlook
Analysts have raised their fair value estimate for Organogenesis Holdings from US$7.00 to US$8.00, citing changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E estimates as key drivers of the updated price target. What's in the News Completed a planned Type-B meeting with the FDA, with confirmation to begin a rolling Biologics License Application (BLA) for ReNu before the end of December (Key Developments).Mise à jour du récit • Dec 18
ORGO: Upcoming Knee Osteoarthritis BLA Filing Will Drive Long Term Upside
Analysts have modestly lifted their price target on Organogenesis Holdings to 8.50 dollars from 8.50 dollars, reflecting slightly higher long term profitability and valuation assumptions despite essentially unchanged growth and fair value estimates. What's in the News Completed a planned Type B FDA meeting confirming the path to initiate a rolling Biologics License Application for ReNu for knee osteoarthritis before the end of December, which advances the regulatory strategy for this lead asset (Key Developments) Raised 2025 guidance and projected net product revenue between 500.0 million dollars and 525.0 million dollars, an increase of 4% to 9% year over year, with expected net income between 8.6 million dollars and 25.4 million dollars (Key Developments) Reported that the second Phase 3 randomized controlled trial of ReNu in knee osteoarthritis did not meet its primary endpoint for statistical significance, but showed numerical pain reduction improvements and maintained a favorable safety profile, supporting plans for an FDA BLA filing (Key Developments) Highlighted that ReNu has been evaluated in three large randomized controlled trials involving more than 1,300 patients and previously received FDA Regenerative Medicine Advanced Therapy designation for knee osteoarthritis, which reinforces its clinical and regulatory foundation (Key Developments) Valuation Changes Fair Value Estimate remained unchanged at 8.50 dollars per share, indicating a stable view of intrinsic equity value.Mise à jour du récit • Dec 04
ORGO: Upcoming Knee Osteoarthritis FDA Filing Will Support Future Share Price Expansion
Analysts have modestly raised their price target on Organogenesis Holdings to 8.50 dollars from 7.50 dollars, citing a slightly higher assumed future price to earnings multiple that more than offsets minor adjustments to the discount rate and margin assumptions. What's in the News Raised 2025 earnings guidance, expecting net product revenue of 500 million to 525 million dollars, up 4% to 9% year over year from 482 million dollars in 2024, with projected net income between 8.6 million and 25.4 million dollars (company guidance).Article d’analyse • Nov 27
Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Shares Bounce 27% But Its Business Still Trails The Industry
Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have had a really impressive month, gaining 27% after a shaky period...Mise à jour du récit • Nov 20
ORGO: Anticipated 2025 Guidance And Promising Data Will Support Share Price Expansion
Analysts have revised their price target for Organogenesis Holdings downward from $8.00 to $7.50. This reflects a tempered outlook based on updated forecasts for revenue growth and profit margins.Mise à jour du récit • Aug 15
CMS Reform And Capacity Expansion Will Unlock Long Term Value
With no change in key metrics such as Future P/E and Net Profit Margin, the consensus analyst price target for Organogenesis Holdings remains steady at $8.00. What's in the News Organogenesis updated full-year 2025 guidance: expects net product revenue between $480 million and $510 million (roughly flat to 6% growth) and net income (loss) ranging from a $6.4 million loss to a $16.4 million profit.Article d’analyse • May 04
Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have been powering on, with a gain of...
Nouveau récit • Apr 25
LCD Delays And ReNu Progress Will Unlock Market Potential
Delay in LCDs implementation offers a chance to capitalize on demand, boosting near-term revenue and market share for key products.Article d’analyse • Mar 02
There's No Escaping Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Muted Revenues Despite A 69% Share Price Rise
The Organogenesis Holdings Inc. ( NASDAQ:ORGO ) share price has done very well over the last month, posting an...Seeking Alpha • Oct 15
Organogenesis: Lurking Disruption With Recovery To Follow
Summary Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025. Liquidity is adequate and excellent potential for acquisition on expected pullbacks. Read the full article on Seeking AlphaArticle d’analyse • Sep 09
Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S
Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong...Article d’analyse • Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope
Key Insights Organogenesis Holdings to hold its Annual General Meeting on 20th of June Salary of US$908.7k is part of...Seeking Alpha • Jun 10
Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Summary Organogenesis has two disproportionate segments, with Surgical and Sports Medicine making up a small portion of revenues. The company's pipeline candidate, ReNu, has the potential to boost Surgical and Sports Medicine revenues. In recent years, Organogenesis has generated inconsistent earnings and may not need to raise cash before launching ReNu. Read the full article on Seeking AlphaArticle d’analyse • May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) recent soft profit numbers didn't appear to worry shareholders, as the...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 301 | -31 | 11 | 27 | 2 |
| 12/31/2027 | 270 | -45 | -9 | 6 | 2 |
| 12/31/2026 | 196 | -198 | -37 | -23 | 2 |
| 6/30/2026 | 457 | -102 | 21 | 32 | N/A |
| 3/31/2026 | 515 | -15 | 17 | 31 | N/A |
| 12/31/2025 | 564 | 20 | -24 | -10 | N/A |
| 9/30/2025 | 465 | -13 | -52 | -39 | N/A |
| 6/30/2025 | 430 | -16 | -46 | -33 | N/A |
| 3/31/2025 | 459 | -20 | -7 | 4 | N/A |
| 12/31/2024 | 482 | -1 | 4 | 14 | N/A |
| 9/30/2024 | 455 | -7 | 4 | 14 | N/A |
| 6/30/2024 | 448 | -17 | 9 | 22 | N/A |
| 3/31/2024 | 435 | 6 | 7 | 26 | N/A |
| 12/31/2023 | 433 | 5 | 7 | 31 | N/A |
| 9/30/2023 | 449 | 13 | -4 | 28 | N/A |
| 6/30/2023 | 457 | 10 | -19 | 17 | N/A |
| 3/31/2023 | 461 | 13 | -16 | 18 | N/A |
| 12/31/2022 | 451 | 16 | -9 | 25 | N/A |
| 9/30/2022 | 463 | 59 | 7 | 35 | N/A |
| 6/30/2022 | 460 | 71 | 23 | 57 | N/A |
| 3/31/2022 | 462 | 83 | 32 | 65 | N/A |
| 12/31/2021 | 467 | 94 | 31 | 62 | N/A |
| 9/30/2021 | 446 | 62 | 36 | 67 | N/A |
| 6/30/2021 | 433 | 69 | 28 | 48 | N/A |
| 3/31/2021 | 379 | 43 | 3 | 21 | N/A |
| 12/31/2020 | 338 | 17 | -12 | 5 | N/A |
| 9/30/2020 | 306 | -5 | -40 | -24 | N/A |
| 6/30/2020 | 270 | -37 | -50 | -38 | N/A |
| 3/31/2020 | 266 | -42 | N/A | -41 | N/A |
| 12/31/2019 | 261 | -39 | N/A | -34 | N/A |
| 9/30/2019 | 250 | -46 | N/A | -45 | N/A |
| 6/30/2019 | 236 | -48 | N/A | -62 | N/A |
| 3/31/2019 | 215 | -58 | N/A | -66 | N/A |
| 12/31/2018 | 193 | -65 | N/A | -61 | N/A |
| 9/30/2018 | 183 | -60 | N/A | -46 | N/A |
| 6/30/2018 | 184 | -52 | N/A | -25 | N/A |
| 3/31/2018 | 187 | -32 | N/A | -9 | N/A |
| 12/31/2017 | 199 | -9 | N/A | -3 | N/A |
| 12/31/2016 | 139 | -17 | N/A | -5 | N/A |
| 12/31/2015 | 99 | -24 | N/A | -10 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ORGO devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: ORGO devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: ORGO devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Les revenus de ORGO devraient diminuer au cours des 3 prochaines années ( -10.8% par an).
Croissance élevée des revenus: Les revenus de ORGO devraient diminuer au cours des 3 prochaines années ( -10.8% par an).
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ORGO devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/20 06:31 |
| Cours de l'action en fin de journée | 2026/09/18 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Organogenesis Holdings Inc. est couverte par 8 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Gorman | BTIG |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Richard Newitter | Leerink Partners LLC |